Lilly to acquire US radiopharmaceutical company POINT for $1.4bn
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Oct 23
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Oct 23
According to the agreement, both firms will co-fund current and future research and development expenditures with Sanofi paying…
03 Oct 23
Baxter’s BioPharma Solutions business will be renamed Simtra BioPharma Solutions (Simtra), which will continue to same solutions and…
03 Oct 23
The drugmaker has received offer for its OTC business, and has agreed to divest its women's healthcare business,…
03 Oct 23
The approval was supported by the positive findings from the Phase 2 PHYOX 2 clinical trial and interim…
03 Oct 23
GSK’s Jemperli plus chemotherapy is now approved for patients with a tumour abnormality called mismatch repair deficient /…
03 Oct 23
The acquisition equips Clade with preclinical cell therapy programmes, a g/d TCR discovery engine, and cell enhancement technologies…
03 Oct 23
Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule
03 Oct 23
The agreement expands the companies' existing relationship, which entails collaborating on IND-enabling preclinical studies for IAMA-6
29 Sep 23
HitGen will leverage its DNA-encoded library (DEL) technology platform for the collaboration, specifically the OpenDEL solution, a self-service…